OBJECTIVES: Analysis of cost containment of SSI via use of Dabigatran Etexilate (150MG) versus current standard of care (Warfarin) in prevention of stroke for non valvular atrial fibrillation patients in Turkish healthcare setting. METHODS: All calculations are performed for a group of 1.000 patients in each treatment arm per year (Treatment arms; Dabigatran 150MG & Warfarin 5MG – results are represented as "cost per patient per day"). Available clinical data is analyzed for calculation of event costs in each treatment arm (RE-LY study). Local costs of events are included from local literature.  Microsoft Excel (2007) is used for calculations and construction of data tables. RESULTS: Direct cost of SSI (indirect costs are not included in this analysis) is calculated in each treatment arm. Difference of daily medication cost between Dabigatran Etexilate and Warfarin treatments is +3.12 TL/Day*Patient however, this difference is calculated as -3.34 TL/Day*Patient when medication cost is combined with total treatment cost (costs of thromboembolic&adverse events, INR monitoring, impairment). Dabigatran Etexilate offers a cost containment (saving) of 0.22 TL/Day*Patient in prevention of stroke for non valvular atrial fibrillation patients in Turkish healthcare setting. CONCLUSIONS: Limitation of this study is covering only direct cost data due to lack of local literature on indirect costs. Further analysis may be performed by non-interventional studies, which will define cost containment data via real life cost and effectiveness values.  This study demonstrates that Dabigatran Etexilate treatment may sustain cost containment (saving) via reduction of direct cost of SSI with respect to current standard of care, in prevention of stroke in patients with atrial fibrillation in current Turkish healthcare system.